Androgen control of lipid metabolism in prostate cancer: novel insights and future applications

Lisa M Butler¹, Margaret M Centenera¹ and Johannes V Swinnen²

¹School of Medicine, University of Adelaide, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia,

²Laboratory of Lipid Metabolism and Cancer, Department of Oncology, LKI – Leuven Cancer Institute, KU Leuven – University of Leuven, Leuven, Belgium

Correspondence should be addressed to J V Swinnen

Email
johan.swinnen@med.kuleuven.be

Abstract

One of the most typical hallmarks of prostate cancer cells is their exquisite dependence on androgens, which is the basis of the widely applied androgen deprivation therapy. Among the variety of key cellular processes and functions that are regulated by androgens, lipid metabolism stands out by its complex regulation and its many intricate links with cancer cell biology. Here, we review our current knowledge on the links between androgens and lipid metabolism in prostate cancer, and highlight recent developments and insights into the links between key oncogenic stimuli and altered lipid synthesis and/or uptake that may hold significant potential for biomarker development and provide new vulnerabilities for therapeutic intervention.

Key Words

- ▶ lipid metabolism
- ▶ phospholipids
- ▶ androgens
- ▶ lipogenic enzymes
- ▶ prostate cancer
- ▶ lipidomics

Endocrine-Related Cancer
(2016) **23**, R219–R227

Androgens and prostate cancer

Prostate cancer is the most commonly diagnosed cancer, and the second leading cause of cancer-related death, in men in the developed world (Jemal *et al.* 2010). In 1941, Huggins and Hodges demonstrated that prostate epithelial cells are dependent on androgenic hormones for growth and survival. Accordingly, the primary treatment for men with metastatic prostate cancer for the past 70 years has been suppression of androgen production by surgical or medical castration, termed androgen deprivation therapy (ADT). While ADT is initially effective (reviewed in Klotz 2008), patients eventually relapse within 18–24 months; this incurable phase of the disease is called castrate-resistant prostate cancer (CRPC) (Asmane *et al.* 2011). Androgens mediate their actions through binding to the androgen receptor (AR), a ligand-dependent transcription factor and a member of the nuclear receptor superfamily. A plethora of adaptive mechanisms including AR

amplification, mutation, and expression of splice variants has been demonstrated to maintain functional receptor signaling in CRPC (Scher *et al.* 2004, Knudsen & Scher 2009, Mills 2014), and consequently AR remains the primary therapeutic target for metastatic and advanced prostate cancer (Knudsen & Scher 2009). The development and FDA approval of agents that more effectively target AR signaling, including enzalutamide (Xtandi; an AR antagonist) and abiraterone acetate (Zytiga; an inhibitor of intratumoral androgen synthesis) (Tran *et al.* 2009, Cai & Balk 2011, Rodrigues *et al.* 2014), has expanded the therapeutic options for CRPC. Nevertheless, even these approaches cannot durably control tumor growth and there is considerable variability in the nature and duration of responses between different patients. Key to improving outcomes for patients with prostate cancer is a more detailed understanding of the key networks of cellular

processes involved in tumor biology that are regulated by androgen action. This will not only reveal new approaches to suppress AR signaling, but also identify biomarkers that can more precisely indicate the optimal treatments for specific patients and monitor their responses.

Altered lipid metabolism is a hallmark of prostate cancer cells

One of the cellular processes most strikingly affected by androgens is lipid metabolism (Swinnen et al. 2006, Zadra et al. 2013). For many years, it has been noted by nuclear magnetic resonance spectroscopy that clinical prostate tumors, particularly more advanced and aggressive cases, often exhibit intense lipid signals, denoted as 'mobile lipids'. These mobile lipids largely correspond to phosphatidylcholine and particularly triglycerides and cholesterol esters found in cellular deposits now known as lipid droplets. Accumulation of lipid droplets has also been demonstrated by other methods including histological staining and Raman spectromicroscopy in more aggressive clinical prostate tumors and metastatic deposits (Yue et al. 2014), and in circulating prostate tumor cells (CTCs) (Mitra et al. 2012). While altered lipid metabolism is acknowledged as a hallmark of many cancers, until relatively recently, it was commonly

regarded as an epiphenomenon that accompanied tumorigenesis. It is now appreciated that cancer cells have a markedly increased need for lipids, which serve as building blocks for membrane production, energy generation and storage, and intracellular signaling. This not only supports deregulated proliferation of cancer cells but also maintains their survival in a hostile microenvironment characterized by hypoxia and limited vascularity (Ackerman & Simon 2014).

While uptake of dietary lipids from the circulation is sufficient for the requirements of most normal cells, lipids are acquired by cancer cells in two main ways (Fig. 1). First, cancer cells overexpress enzymes in order to synthesize lipids *de novo*, and this cellular shift to *de novo* lipogenesis is associated with poorer prognosis for a wide range of tumor types, including prostate and breast cancers (Swinnen et al. 2006, Menendez & Lupu 2007). Activation of this pathway involves changes at all levels of lipid enzyme regulation (genetic changes, enhanced transcription and translation, protein stabilization and phosphorylation, allosteric regulation and substrate flux) and occurs downstream of various common oncogenic events, including loss of *PTEN*, activation of Akt, loss or mutation of *p53* or *BRCA1*, steroid hormone action, and tumor-associated hypoxia (Kuhajda 2006, Swinnen et al. 2006, Wang et al. 2013, Naguib et al. 2015, Rueda-Rincon

Figure 1

Androgens influence both synthesis and uptake of fatty acids in prostate cells. By activating SREBP1, the master regulator of lipid metabolism, androgens bound to the androgen receptor (AR) to stimulate the transcription of enzymes required for *de novo* lipogenesis and receptors that mediate the uptake of fatty acids released by lipolysis from the circulation and adipocytes. More recent evidence implicates direct activation of lipogenic gene transcription by AR signaling as an alternate mechanism by which androgens regulate fatty acid metabolism. Within the cell, fatty acids may then be oxidized for energy, stored as energy in lipid droplets, or converted to more complex phospholipids and incorporated into cellular membranes.

et al. 2015). Secondly, cancer cells can take up exogenous lipids from the circulation and actively stimulate mobilization and release of stored lipids from intracellular lipid droplets or adipocytes in the tumor microenvironment, a process called lipolysis (Kuemmerle *et al.* 2011, Zaidi *et al.* 2013). Prostate cancer cells differ from many other cancer types, in that they predominantly utilize these fatty acids as energetic substrates, rather than glucose (Liu *et al.* 2010). This process is comparatively understudied in contrast to *de novo* lipogenesis; however, there is an increasing view that both are likely to be important sources of lipids to support prostate cancer cell proliferation (Zaidi *et al.* 2013).

Fatty acids that are synthesized or acquired by prostate cancer cells undergo catabolism via beta-oxidation for energy production (Carracedo *et al.* 2013), are stored in lipid droplets to protect them from harmful peroxidation (Bailey *et al.* 2015, Liu *et al.* 2015), or are ultimately converted to more complex phospholipids that are key components of cellular membranes (Fig. 1). Phospholipids are composed of a polar headgroup (e.g. choline, ethanolamine, serine, inositol) and fatty acyl chains that can differ both in length and the number of unsaturations (double bonds), leading to hundreds of different potential lipid species. Because mammalian cells lack the enzyme delta-12 desaturase to generate polyunsaturated acyl chains *de novo*, newly synthesized lipids are enriched in saturated and monounsaturated fatty acid chains. Consequently, enhanced lipogenesis not only helps meet the increased need of tumor cells for membranes to support rapid cell proliferation, it also enhances membrane phospholipid saturation (Rysman *et al.* 2010), which significantly affects numerous aspects of cancer cell biology. Functioning as barriers that separate and compartmentalize the cell's content, membranes play a central role in cell biology as unique interfaces at which numerous cellular processes (including signaling, nutrient transport, cell division, respiration, and cell death mechanisms) are concentrated and regulated. Membranes are also remarkably fluid structures, in which its constituent lipids readily diffuse throughout the plane of the bilayer, and this fluidity is regulated by the composition of phospholipids and cholesterol in the membrane. Fully saturated lipids pack densely into the plasma membrane, resulting in more rigid, impermeable membranes, and tend to partition into detergent-resistant membrane microdomains that are involved in the activation of oncogenic signaling pathways (Swinnen *et al.* 2003). Unsaturated lipids, on the other hand, pack less densely due to the presence of double bonds causing 'kinks' in the acyl chains, thereby

enhancing membrane fluidity. As a result of *de novo* lipogenesis, membranes enriched for more saturated lipid species have altered polarity and loss of the cellular sensory cilia (Willemarck *et al.* 2010, Gijs *et al.* 2015), and are highly resistant to free radical damage, immune recognition, cell death, and chemotherapeutic insults (Rysman *et al.* 2010). Interestingly, recent evidence indicates that the synthesis of unsaturated lipids also plays a key role in cancer cell survival in response to hypoxia or oncogenic signals, by relieving endoplasmic reticulum stress (Young *et al.* 2013). In view of the emerging evidence that altered lipid metabolism affects numerous aspects of cancer cell biology, it is likely that changes in the composition of lipid species in a cell (i.e. the 'lipidome') serve to support the cancer phenotype (Santos & Schulze 2012).

Lipid metabolism is androgen-regulated in prostate cancer

In benign and malignant prostate cells, androgens have a marked stimulatory effect on multiple metabolic pathways, including lipid metabolism (Rysman *et al.* 2010, Barfeld *et al.* 2014). In the normal prostate, this anabolic action is essential to maintain the secretory function of the prostate gland required for optimal male fertility. In the case of tumor cells, we observed in 1996 that exposure of LNCaP prostate cells to natural or synthetic androgens leads to a marked accumulation of lipid droplets in the cytoplasm, largely via increased synthesis of fatty acids and cholesterol (Swinnen *et al.* 1996). Importantly, this lipogenesis was reversed by an AR antagonist and was not observed in AR-negative prostate cancer cells. Since that first key observation, androgens have been shown to stimulate expression of over 20 enzymes involved in lipid synthesis, binding, uptake, metabolism, and transport (Swinnen *et al.* 1997, Swinnen *et al.* 2004, Barfeld *et al.* 2014), thereby influencing the entire lipid profile of prostate cells in a coordinated manner.

Androgens stimulate lipid synthesis, uptake, and storage

De novo lipogenesis describes the conversion of acetyl-coenzyme A (acetyl-CoA, generated from citrate or acetate) to basic saturated fatty acids. The rate-limiting step in this process is the conversion of acetyl-CoA to malonyl-CoA, which is catalyzed by the enzyme acetyl-CoA carboxylase (ACC). Fatty acid synthase (FASN) then couples acetyl and malonyl groups to produce long-chain saturated fatty acids (mainly palmitic acid, C16:0), and

stearoyl-CoA desaturase (SCD) converts saturated fatty acids such as palmitic acid to monounsaturated species. Elongases (ELOVLs), of which there are seven family members, catalyze the elongation of fatty acids, with different family members having different specificities for chain length and saturation level. It is well documented that the expression of each of these classes of enzymes, as well as those involved in cholesterol synthesis, is regulated by androgens (Swinnen *et al.* 1997, Gorlov *et al.* 2009, Massie *et al.* 2011, Sharma *et al.* 2013).

While most research attention has focused on the actions of androgens on *de novo* lipogenesis, AR signaling may also regulate cellular uptake of exogenous lipids by prostate cancer cells (Pinthus *et al.* 2007, Liu *et al.* 2010, Mitra *et al.* 2012, Sacca *et al.* 2012, Taylor *et al.* 2015). These lipids can be derived from dietary lipoproteins in the circulation, which are hydrolyzed by lipoprotein lipase to free fatty acids, or be released by lipolysis from stores in local adipose tissue depots that comprises a major component of the tumor microenvironment (Ribeiro *et al.* 2012). Androgens are generally viewed to stimulate lipolysis of fatty acids from adipocytes (O'Reilly *et al.* 2014), and have been reported to induce the expression of cell surface proteins that regulate the uptake of lipids from the extracellular microenvironment, including phosphatidic acid phosphatase type 2 (Ulrix *et al.* 1998) and plasma membrane fatty acid binding protein (Pinthus *et al.* 2007). Collectively, these actions of androgens could result in a vicious cycle of fatty acid release from the adipose-rich tumor microenvironment and enhanced uptake by the tumor cells. The volume and composition of the adipose tissue is altered by metabolic syndrome or obesity, which may in turn influence lipid availability and utilization. While there is conflicting data on the effect of obesity on the risk of developing prostate cancer, there is now strong evidence that obese men have more aggressive disease at diagnosis and a higher rate of recurrence following surgery (reviewed in Balaban *et al.* (2015), Taylor *et al.* (2015)). In cell line models, lipids taken up by prostate cancer cells can drive proliferation (Nieman *et al.* 2013) and potentially invasiveness (Sacca *et al.* 2012). Moreover, a recent report has demonstrated enhanced migration of prostate cancer cells induced by coculture with periprosthetic-derived adipocytes from obese compared with lean mice (Laurent *et al.* 2016). Given that the antitumor effects of inhibiting lipogenesis can be overcome by providing exogenous fatty acids (Kuemmerle *et al.* 2011, Griffiths *et al.* 2013, Daniels *et al.* 2014), uptake of fatty acids by prostate tumor cells

may be an important mechanism of clinical resistance to inhibitors of lipid synthesis (e.g. FASN inhibitors), particularly in a setting of obesity. Combining these agents with either AR-targeting strategies or lipid uptake inhibitors may be a useful strategy to limit acquisition of lipids by prostate cancer cells and achieve more durable patient responses.

Mechanisms of androgenic regulation of lipid metabolism

Currently, the best-characterized mechanism by which androgens may stimulate *de novo* lipogenesis and lipid uptake is through indirect activation of a family of transcription factors called sterol regulatory element-binding proteins (SREBPs) (Swinnen *et al.* 1997) (reviewed in Heemers *et al.* (2006)). SREBPs, comprising SREBP1a, 1c, and 2 isoforms, regulate the expression of most of the enzymes required for lipid synthesis and uptake, making them master regulators of lipid homeostasis in cells. In their inactive form, SREBPs are anchored to the endoplasmic reticulum membrane as part of a complex containing SCAP (SREBP cleavage activating protein) and INSIGs (insulin-induced genes-1 and -2) (Fig. 2). In response to decreased intracellular sterol levels, the interaction between SCAP and INSIG is lost and the SCAP–SREBP complex translocates to the Golgi, where it undergoes cleavage by site-1 and site-2 proteases. The resultant N-terminal domain of SREBP translocates into the nucleus, where it binds to specific sterol-response elements (SREs) to induce transcription of many of the key enzymes involved in *de novo* lipogenesis. Phosphorylation of SREBP by the energy sensor 5'AMP-activated kinase (AMPK) can prevent this proteolysis and nuclear translocation (Li *et al.* 2011). Inhibition of SREBP1 activity has been achieved by shRNA knockdown or the synthetic inhibitor fatostatin, and indirectly by activation of the energy sensor AMPK by agents such as silibinin. Each of these approaches result in repressed expression of key enzymes involved in lipogenesis, reduced cellular levels of fatty acids, and suppressed growth of tumor xenografts for a range of cultured prostate cell lines (AR-positive and AR-negative) (Huang *et al.* 2012, Li *et al.* 2014, Nambiar *et al.* 2014, Zadra *et al.* 2014, Nambiar *et al.* 2015). In the case of silibinin, these effects were restricted to tumor and not nonmalignant prostate cell lines (Nambiar *et al.* 2014). Collectively, this evidence supports a key role for SREBP-directed lipogenesis in supporting growth and survival of prostate tumor cells.

Figure 2

Mechanism of androgenic regulation of lipid metabolism. Androgens exert their effects by binding to the androgen receptor (AR), a ligand-activated transcription factor. While there is evidence that the AR can directly activate transcription of lipogenic enzymes, the best-characterized mechanism by which AR stimulates fatty acid metabolism is via activation of SREBPs. Direct induction of the SREBP cleavage-activating protein (SCAP) gene by AR facilitates translocation of SREBP1 to the Golgi for cleavage. The resultant activation of SREBP1 stimulates transcription of a large suite of genes required for lipogenesis and fatty acid uptake, including the AR itself.

The interactions between androgens and SREBPs are complex and remain incompletely understood. Androgens enhance both the expression and activation of SREBPs (Swinnen *et al.* 1997), although this is indirect, being mediated not by the transcriptional activity of the AR, but rather autoregulation of SREBP transcription as a result of activation via proteolytic cleavage of SREBP (Swinnen *et al.* 1997). More recent evidence indicates that this activation may be mediated via transcriptional induction of SCAP levels via binding of the AR to an ARE in the body of the SCAP gene (Fig. 2), thereby favoring translocation of SREBP precursors to the Golgi for cleavage (Heemers *et al.* 2004, Zhou *et al.* 2012). SREBPs can reciprocally activate the expression of AR via binding to an SRE in the 5'-untranslated region of the AR gene (Fig. 2) (Huang *et al.* 2010), and modulation of SREBP1 activity has parallel effects on AR expression and function (Fig. 2) (Huang *et al.* 2012, Li *et al.* 2014). Collectively, these mechanisms indicate that androgens can exert a coordinate and profound control over lipogenesis in both normal and neoplastic cell settings, and that normally this is tightly regulated by the reciprocal relationship between AR and SREBP activity.

Recent studies have provided new mechanistic insights into the link between SREBP, androgens, and uptake of extracellular lipids in prostate cancer cells. Investigators associated specific accumulation of esterified cholesterol within the lipid droplets of clinical prostate tumors, which was most pronounced in high-grade

disease, with loss of *PTEN* and resultant activation of the PI3K/Akt pathway (Yue *et al.* 2014). Akt-mediated induction of SREBP in turn upregulated the expression of low-density lipoprotein (LDL) receptor on the cell surface, and enhanced the uptake of free cholesterol, which was then esterified and incorporated into lipid droplets. Interference with this pathway suppressed prostate cancer growth *in vitro* and *in vivo* and represents a promising therapeutic strategy. While this study did not find a direct relationship between androgen signaling and cholesterol uptake by the prostate cell lines, the protein Plk1, a mediator of oxidative stress in prostate cancer cells in response to stress stimuli such as androgen deprivation, has been implicated as a key upstream activator of the PI3K pathway (Zhang *et al.* 2014). PI3K/Akt signaling exhibits bidirectional crosstalk with AR signaling (Carver *et al.* 2011, Qi *et al.* 2015, Gao *et al.* 2016), providing a further level of complexity as both PI3K/Akt and AR lie upstream of SREBP activity and have the potential to either enhance or interfere with each other's ability to regulate lipogenesis and lipid uptake.

Recent genome-wide analyses of AR binding and activity have suggested a potentially distinct role for the AR in direct transcriptional regulation of lipogenic genes. Canonical AR action involves nuclear translocation of the ligand-bound receptor and binding as a dimer to specific DNA sequences found in AR binding sites (ARs), often in the vicinity of androgen-regulated genes. This DNA binding precedes the recruitment of transcriptional machinery

and coregulators, and results in altered gene transcription. Cistromic data of AR binding in chromatin of prostate cancer cells and clinical tumors have revealed that ARBs commonly occur in the vicinity (within 25 kb) of genes involved in general cellular and lipid metabolism (Barfeld *et al.* 2014). Based on their proximity to AR binding sites, and their transcriptional regulation by androgens, many genes involved in lipid metabolism (e.g. FASN, ACACA) and other key cellular metabolic processes have the potential to be directly regulated by the AR in both nonmalignant and malignant prostate cells (Massie *et al.* 2011, Sharma *et al.* 2013). This indicates that, in addition to their effects on SREBPs, androgens may also directly stimulate a coordinated metabolic network that enhances aerobic glycolysis and lipid biosynthesis, thereby supporting tumor cell growth and survival. Interestingly, inspection of the transcriptional data reveals marked variability in the extent and timecourse of transcriptional regulation between individual lipogenic genes by androgens, indicating that there is most likely a combination of direct and indirect mechanisms involved. Ablation of the putative ARBs in the vicinity of these genes will be essential to confirm direct regulation by androgens. The fact that targeting of many of these metabolic pathways has been the subject of intense investigation will underpin the design of rational combinatorial strategies to cotarget the AR and its metabolic target genes or pathways involved in lipid and general cellular metabolism.

Genes involved in lipid metabolism are altered in clinical prostate tumors

The clinical significance of the relationship between androgens and lipid metabolism is highlighted by reports that FASN, ELOVL7, and SREBP proteins are commonly overexpressed in human prostate tumors compared with normal or benign prostatic hypertrophic tissue (Swinnen *et al.* 2002, Rossi *et al.* 2003, Ettinger *et al.* 2004, Tamura *et al.* 2009), with the expression of SREBP1 in particular showing positive associations with disease progression and Gleason grade (Ettinger *et al.* 2004, Huang *et al.* 2012). Consistent with their androgenic regulation, both FASN and SREBP levels are initially decreased in patients treated with ADT but re-emerge with a higher level of expression in CRPC (Rossi *et al.* 2003, Ettinger *et al.* 2004). Moreover, interrogation of publicly available mRNA datasets has revealed significant increases in the expression of SREBP and multiple androgen-regulated genes involved in lipid metabolism and beta-oxidation in prostate tumors compared with nonmalignant prostate (Wu *et al.* 2014).

In light of these observations, targeting the metabolic and lipidomic features of tumor cells is a rational therapeutic strategy, and is the subject of several recent excellent reviews (Fritz *et al.* 2013, Comerford *et al.* 2014). FASN in particular has received considerable attention as a potential therapeutic target (Mullen & Yet 2015) and small molecule inhibitors of FASN, including the antiobesity agent orlistat, have demonstrated promising preclinical efficacy in prostate tumor models (reviewed in Menendez & Lupu (2007), Zadra *et al.* (2013), Wu *et al.* (2014)). Unfortunately, despite active drug discovery efforts, the clinical translation of these agents to date has been limited by unacceptable toxicity profiles (Mullen & Yet 2015).

Lipidomics: the understudied 'omic'

The fundamental role of androgens in regulating lipid metabolism has fuelled interest in studying the composition of lipids (i.e. the lipidome) in prostate tumors as a novel source of biomarkers of disease aggressiveness and response to AR-directed therapies. In contrast to the genome, transcriptome, or proteome, the lipidome and particularly the phospholipidome remain poorly explored as sources of biological information on the status or behavior of a cell. This is partly due to the requirement for state-of-the-art instrumentation and expertise to accurately and simultaneously measure the thousands of different lipid species present within a cell or tissue (Wenk 2010, Checa *et al.* 2015). However, recent developments in mass spectrometry methodologies and efforts to define phospholipid profiles in blood, cancer cells, and tissues have enabled the documentation of recurrent changes in prostate cancer cells compared with nonmalignant cells, and have facilitated the identification of specific lipid classes that are qualitatively and quantitatively altered in more aggressive metastatic cells (Rysman *et al.* 2010, Burch *et al.* 2015, Goto *et al.* 2015, Duscharla *et al.* 2016). MALDI (mass spectrometry imaging), Raman spectroscopy, and development of molecular probes directed to specific lipids afford novel opportunities to investigate not only the quantity but also the spatial distribution of specific lipids within a cell or tissue. Such analyses are instrumental for the identification of novel key changes in lipid metabolic pathways in cancer and hold great potential for lipid-based biomarker discovery and applications, including smart knife technologies. Moreover, as changes in lipid profiles can be measured in body fluids, and potentially visualized in tumors by molecular imaging, there is a high potential for the development of specific and minimally invasive tests. Most recently, advances are being made in

the integration of lipidomic data with other 'omics' such as transcriptomics (Li *et al.* 2016). While challenging, this integration offers the exciting potential to use data-driven system approaches to identify key drivers of metabolic alterations, which may represent previously unrecognized therapeutic or preventative targets. Nevertheless, it remains impossible to measure the entire lipidome simultaneously using a single assay system, and the ability to feasibly perform targeted and quantitative lipidomic analysis in a healthcare setting will be essential to the future adoption of lipid-based biomarkers for disease prognostication, drug development, and treatment response (Zhang & Wakelam 2014, Dehairs *et al.* 2015, Hyotylainen & Oresic 2015).

Summary and perspective

Despite being markedly altered in prostate cancer, exquisitely sensitive to androgen hormones, and tightly linked to cancer cell biology, the potential of lipid metabolism to provide new information about the clinical behavior of prostate cancer and new targets for therapeutic intervention has not yet been fully realized. The intimate links between androgen signaling, oncogenic pathways, and lipid metabolism in prostate cancer cells make the prostate cancer lipidome a potentially unique indicator of tumor behavior and aggressiveness, and a source of novel therapeutic targets. Moreover, as current treatments for high-risk or advanced prostate cancer are specific inhibitors of androgen production or androgen binding to the AR, they would be expected to markedly alter the expression of enzymes involved in lipid metabolism in prostate cancer cells. In view of the dramatic changes in lipid metabolism evoked by androgens, lipidomics may be particularly advantageous as a means of monitoring the response of clinical prostate tumors to these antiandrogen therapies or progression to a castrate-resistant state. As expertise in lipid analysis becomes more widespread, and technologies improve in sensitivity and resolution, lipidomics will likely join metabolomics as complex and informative readouts of tumor biology, metabolism, and biomarker discovery.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

L M B is supported by a Future Fellowship from the Australian Research Council (FT130101004); M M C is supported by a Young Investigator Award

(ID 0412) from the Prostate Cancer Foundation of Australia. L M B, M M C, and J V S acknowledge funding from the Movember Foundation through the Prostate Cancer Foundation of Australia (MRTA3) and the Prostate Cancer Foundation of Australia (ID 2711). J V S acknowledges funding from KU Leuven (GOA/11/009 and C16/15/073) and the Fund for Scientific Research Flanders (FWO) (G.0691.12 and G.0841.15).

Acknowledgments

The authors thank many colleagues and collaborators for helpful discussions.

References

- Ackerman D & Simon MC 2014 Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. *Trends in Cell Biology* **24** 472–478. (doi:10.1016/j.tcb.2014.06.001)
- Asmane I, Ceraline J, Duclos B, Rob L, Litique V, Barthelemy P, Bergerat JP, Dufour P & Kurtz JE 2011 New strategies for medical management of castration-resistant prostate cancer. *Oncology* **80** 1–11. (doi:10.1159/000323495)
- Bailey AP, Koster G, Guillermier C, Hirst EM, MacRae JI, Lechene CP, Postle AD & Gould AP 2015 Antioxidant role for lipid droplets in a stem cell niche of drosophila. *Cell* **163** 340–353. (doi:10.1016/j.cell.2015.09.020)
- Balaban S, Lee LS, Schreuder M & Hoy AJ 2015 Obesity and cancer progression: is there a role of fatty acid metabolism? *Biomed Research International* **2015** 274585. (doi:10.1155/2015/274585)
- Barfeld SJ, Ikonen HM, Urbanucci A & Mills IG 2014 Androgen-regulated metabolism and biosynthesis in prostate cancer. *Endocrine-Related Cancer* **21** T57–T66. (doi:10.1530/ERC-13-0515)
- Burch TC, Isaac G, Booher CL, Rhim JS, Rainville P, Langridge J, Baker A & Nyalwidhe JO 2015 Comparative metabolomic and lipidomic analysis of phenotype stratified prostate cells. *PLoS ONE* **10** e0134206. (doi:10.1371/journal.pone.0134206)
- Cai C & Balk SP 2011 Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy. *Endocrine-Related Cancer* **18** R175–R182. (doi:10.1530/ERC-10-0339)
- Carracedo A, Cantley LC & Pandolfi PP 2013 Cancer metabolism: fatty acid oxidation in the limelight. *Nature Reviews Cancer* **13** 227–232. (doi:10.1038/nrc3483)
- Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J, Scher H, *et al.* 2011 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. *Cancer Cell* **19** 575–586. (doi:10.1016/j.ccr.2011.04.008)
- Checa A, Bedia C & Jaumot J 2015 Lipidomic data analysis: tutorial, practical guidelines and applications. *Analytica Chimica Acta* **885** 1–16. (doi:10.1016/j.aca.2015.02.068)
- Comerford SA, Huang Z, Du X, Wang Y, Cai L, Witkiewicz AK, Walters H, Tantawy MN, Fu A, Manning HC, *et al.* 2014 Acetate dependence of tumors. *Cell* **159** 1591–1602. (doi:10.1016/j.cell.2014.11.020)
- Daniels VW, Smans K, Royaux I, Chypre M, Swinnen JV & Zaidi N 2014 Cancer cells differentially activate and thrive on de novo lipid synthesis pathways in a low-lipid environment. *PLoS ONE* **9** e106913. (doi:10.1371/journal.pone.0106913)
- Dehairs J, Derua R, Rueda-Rincon N & Swinnen JV 2015 Lipidomics in drug development. *Drug Discovery Today Technologies* **13** 33–38. (doi:10.1016/j.ddtec.2015.03.002)
- Duscharla D, Bhumireddy SR, Lakshetti S, Pospisil H, Murthy PV, Walther R, Sripadi P & Ummanni R 2016 Prostate cancer associated lipid signatures in serum studied by ESI-tandem mass spectrometry as potential new biomarkers. *PLoS ONE* **11** e0150253. (doi:10.1371/journal.pone.0150253)
- Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME & Nelson CC 2004 Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during

- progression to androgen independence. *Cancer Research* **64** 2212–2221. (doi:10.1158/0008-5472.CAN-2148-2)
- Fritz V, Benfodda Z, Henriquet C, Hure S, Cristol JP, Michel F, Carbonneau MA, Casas F & Fajas L 2013 Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth. *Oncogene* **32** 5101–5110. (doi:10.1038/onc.2012.523)
- Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, et al. 2016 ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer. *Clinical Cancer Research* [in press]. (doi:10.1158/1078-0432.CCR-15-2309)
- Gijls HL, Willemarck N, Vanderhoydonc F, Khan NA, Dehairs J, Derua R, Waelkens E, Taketomi Y, Murakami M, Agostinis P, et al. 2015 Primary cilium suppression by SREBP1c involves distortion of vesicular trafficking by PLA2G3. *Molecular Biology of the Cell* **26** 2321–2332. (doi:10.1091/mbc.E14-10-1472)
- Gorlov IP, Byun J, Gorlova OY, Aparicio AM, Efsthathiou E & Logothetis CJ 2009 Candidate pathways and genes for prostate cancer: a meta-analysis of gene expression data. *BMC Medical Genomics* **2** 48. (doi:10.1186/1755-8794-2-48)
- Goto T, Terada N, Inoue T, Kobayashi T, Nakayama K, Okada Y, Yoshikawa T, Miyazaki Y, Uegaki M, Utsunomiya N, et al. 2015 Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer. *Prostate* **75** 1821–1830. (doi:10.1002/pros.23088)
- Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, Konisti S, Peck B, Miess H, East P, et al. 2013 Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. *Cancer & Metabolism* **1** 3. (doi:10.1186/2049-3002-1-3)
- Heemers H, Verrijdt G, Organe S, Claessens F, Heyns W, Verhoeven G & Swinnen JV 2004 Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. *Journal of Biological Chemistry* **279** 30880–30887. (doi:10.1074/jbc.M401615200)
- Heemers HV, Verhoeven G & Swinnen JV 2006 Androgen activation of the sterol regulatory element-binding protein pathway: current insights. *Molecular Endocrinology* **20** 2265–2277. (doi:10.1210/me.2005-0479)
- Huang WC, Zhau HE & Chung LW 2010 Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. *Journal of Biological Chemistry* **285** 7947–7956. (doi:10.1074/jbc.M109.092759)
- Huang WC, Li X, Liu J, Lin J & Chung LW 2012 Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. *Molecular Cancer Research* **10** 133–142. (doi:10.1158/1541-7786.MCR-11-0206)
- Hyotylainen T & Oresic M 2015 Optimizing the lipidomics workflow for clinical studies – practical considerations. *Analytical and Bioanalytical Chemistry* **407** 4973–4993. (doi:10.1007/s00216-015-8633-2)
- Jemal A, Siegel R, Xu J & Ward E 2010 Cancer statistics, 2010. *CA Cancer Journal for Clinicians* **60** 277–300. (doi:10.3322/caac.20073)
- Klotz L 2008 Maximal androgen blockade for advanced prostate cancer. *Best Practice & Research. Clinical Endocrinology & Metabolism* **22** 331–340.
- Knudsen KE & Scher HI 2009 Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. *Clinical Cancer Research* **15** 4792–4798. (doi:10.1158/1078-0432.CCR-08-2660)
- Kuemmerle NB, Rysman E, Lombardo PS, Flanagan AJ, Lipe BC, Wells WA, Pettus JR, Froehlich HM, Memoli VA, Morganelli PM, et al. 2011 Lipoprotein lipase links dietary fat to solid tumor cell proliferation. *Molecular Cancer Therapeutics* **10** 427–436. (doi:10.1158/1535-7163.MCT-10-0802)
- Kuhajda FP 2006 Fatty acid synthase and cancer: new application of an old pathway. *Cancer Research* **66** 5977–5980. (doi:10.1158/0008-5472.CAN-05-4673)
- Laurent V, Guerard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, Zaidi F, Majed B, Garandeau D, Socrier Y, et al. 2016 Periprosthetic adipocytes act as a driving force for prostate cancer progression in obesity. *Nature Communications* **7** 10230. (doi:10.1038/ncomms10230)
- Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al. 2011 AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. *Cell Metabolism* **13** 376–388. (doi:10.1016/j.cmet.2011.03.009)
- Li X, Chen YT, Hu P & Huang WC 2014 Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. *Molecular Cancer Therapeutics* **13** 855–866. (doi:10.1158/1535-7163.MCT-13-0797)
- Li J, Ren S, Piao HL, Wang F, Yin P, Xu C, Lu X, Ye G, Shao Y, Yan M, et al. 2016 Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. *Scientific Reports* **6** 20984. (doi:10.1038/srep20984)
- Liu L, Zhang K, Sandoval H, Yamamoto S, Jaiswal M, Sanz E, Li Z, Hui J, Graham BH, Quintana A, et al. 2015 Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration. *Cell* **160** 177–190. (doi:10.1016/j.cell.2014.12.019)
- Liu Y, Zuckier LS & Ghesani NV 2010 Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. *Anticancer Research* **30** 369–374.
- Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A, Scott H, Madhu B, Sharma N, et al. 2011 The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. *EMBO Journal* **30** 2719–2733. (doi:10.1038/emboj.2011.158)
- Menendez JA & Lupu R 2007 Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. *Nature Reviews Cancer* **7** 763–777. (doi:10.1038/nrc2222)
- Mills IG 2014 Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. *Nature Reviews Cancer* **14** 187–198. (doi:10.1038/nrc3678)
- Mitra R, Chao O, Urasaki Y, Goodman OB & Le TT 2012 Detection of lipid-rich prostate circulating tumour cells with coherent anti-Stokes Raman scattering microscopy. *BMC Cancer* **12** 540. (doi:10.1186/1471-2407-12-540)
- Mullen GE & Yet L 2015 Progress in the development of fatty acid synthase inhibitors as anticancer targets. *Bioorganic & Medicinal Chemistry Letters* **25** 4363–4369. (doi:10.1016/j.bmcl.2015.08.087)
- Naguib A, Bencze G, Engle DD, Chio IL, Herzka T, Watrud K, Bencze S, Tveson DA, Pappin DJ & Trotman LC 2015 p53 mutations change phosphatidylinositol acyl chain composition. *Cell Reports* **10** 8–19. (doi:10.1016/j.celrep.2014.12.010)
- Nambiar DK, Deep G, Singh RP, Agarwal C & Agarwal R 2014 Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. *Oncotarget* **5** 10017–10033.
- Nambiar DK, Rajamani P & Singh RP 2015 Silibinin attenuates ionizing radiation-induced pro-angiogenic response and EMT in prostate cancer cells. *Biochemical and Biophysical Research Communications* **456** 262–268. (doi:10.1016/j.bbrc.2014.11.069)
- Nieman KM, Romero IL, Van Houten B & Lengyel E 2013 Adipose tissue and adipocytes support tumorigenesis and metastasis. *Biochimica et Biophysica Acta* **1831** 1533–1541. (doi:10.1016/j.bbalip.2013.02.010)
- O'Reilly MW, House PJ & Tomlinson JW 2014 Understanding androgen action in adipose tissue. *Journal of Steroid Biochemistry and Molecular Biology* **143** 277–284. (doi:10.1016/j.jsmb.2014.04.008)
- Pinthus JH, Lu JP, Bidaisee LA, Lin H, Bryskine I, Gupta RS & Singh G 2007 Androgen-dependent regulation of medium and long chain fatty acids uptake in prostate cancer. *Prostate* **67** 1330–1338. (doi:10.1002/pros.20609)
- Qi W, Morales C, Cooke LS, Johnson B, Somer B & Mahadevan D 2015 Reciprocal feedback inhibition of the androgen receptor and PI3K as

- a novel therapy for castrate-sensitive and -resistant prostate cancer. *Oncotarget* **6** 41976–41987. (doi:10.18632/oncotarget.5659)
- Ribeiro R, Monteiro C, Cunha V, Oliveira MJ, Freitas M, Fraga A, Principe P, Lobato C, Lobo F, Morais A, et al. 2012 Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. *Journal of Experimental & Clinical Cancer Research* **31** 32. (doi:10.1186/1756-9966-31-32)
- Rodrigues DN, Butler LM, Estelles DL & de Bono JS 2014 Molecular pathology and prostate cancer therapeutics: from biology to bedside. *Journal of Pathology* **232** 178–184. (doi:10.1002/path.4272)
- Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S & Loda M 2003 Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. *Molecular Cancer Research* **1** 707–715.
- Rueda-Rincon N, Bloch K, Derua R, Vyas R, Harms A, Hankemeier T, Khan NA, Dehairs J, Bagadi M, Binda MM, et al. 2015 p53 attenuates AKT signaling by modulating membrane phospholipid composition. *Oncotarget* **6** 21240–21254. (doi:10.18632/oncotarget)
- Rysman E, Brusselmans K, Scheys K, Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D, Daniels VW, Machiels J, et al. 2010 De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. *Cancer Research* **70** 8117–8126. (doi:10.1158/0008-5472.CAN-09-3871)
- Sacca PA, Creydt VP, Choi H, Mazza ON, Fletcher SJ, Vallone VB, Scorticati C, Chasseing NA & Calvo JC 2012 Human periprostatic adipose tissue: its influence on prostate cancer cells. *Cellular Physiology and Biochemistry* **30** 113–122. (doi:10.1159/000339051)
- Santos CR & Schulze A 2012 Lipid metabolism in cancer. *FEBS Journal* **279** 2610–2623. (doi:10.1111/j.1742-4658.2012.08644.x)
- Scher HI, Buchanan G, Gerald W, Butler LM & Tilley WD 2004 Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. *Endocrine-Related Cancer* **11** 459–476. (doi:10.1677/erc.1.00525)
- Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG, et al. 2013 The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. *Cancer Cell* **23** 35–47. (doi:10.1016/j.ccr.2012.11.010)
- Swinnen JV, Van Veldhoven PP, Esquenet M, Heyns W & Verhoeven G 1996 Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. *Endocrinology* **137** 4468–4474.
- Swinnen JV, Ulrix W, Heyns W & Verhoeven G 1997 Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. *PNAS* **94** 12975–12980. (doi:10.1073/pnas.94.24.12975)
- Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, Heyns W & Verhoeven G 2002 Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. *International Journal of Cancer* **98** 19–22. (doi:10.1002/ijc.10127)
- Swinnen JV, Van Veldhoven PP, Timmermans L, De Schrijver E, Brusselmans K, Vanderhoydonc F, Van de Sande T, Heemers H, Heyns W & Verhoeven G 2003 Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. *Biochemical and Biophysical Research Communications* **302** 898–903. (doi:10.1016/S0006-291X(03)00265-1)
- Swinnen JV, Heemers H, van de Sande T, de Schrijver E, Brusselmans K, Heyns W & Verhoeven G 2004 Androgens, lipogenesis and prostate cancer. *Journal of Steroid Biochemistry and Molecular Biology* **92** 273–279. (doi:10.1016/j.jsbmb.2004.10.013)
- Swinnen JV, Brusselmans K & Verhoeven G 2006 Increased lipogenesis in cancer cells: new players, novel targets. *Current Opinion in Clinical Nutrition and Metabolic Care* **9** 358–365. (doi:10.1097/01.mco.0000232894.28674.30)
- Tamura K, Makino A, Hullin-Matsuda F, Kobayashi T, Furihata M, Chung S, Ashida S, Miki T, Fujioka T, Shuin T, et al. 2009 Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. *Cancer Research* **69** 8133–8140. (doi:10.1158/0008-5472.CAN-09-0775)
- Taylor RA, Lo J, Ascui N & Watt MJ 2015 Linking obesogenic dysregulation to prostate cancer progression. *Endocrine Connections* **4** R68–R80. (doi:10.1530/EC-15-0080)
- Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, et al. 2009 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. *Science* **324** 787–790. (doi:10.1126/science.1168175)
- Ulrix W, Swinnen JV, Heyns W & Verhoeven G 1998 Identification of the phosphatidic acid phosphatase type 2a isozyme as an androgen-regulated gene in the human prostatic adenocarcinoma cell line LNCaP. *Journal of Biological Chemistry* **273** 4660–4665. (doi:10.1074/jbc.273.8.4660)
- Wang X, Zhao X, Gao X, Mei Y & Wu M 2013 A new role of p53 in regulating lipid metabolism. *Journal of Molecular Cell Biology* **5** 147–150. (doi:10.1093/jmcb/mjs064)
- Wenk MR 2010 Lipidomics: new tools and applications. *Cell* **143** 888–895. (doi:10.1016/j.cell.2010.11.033)
- Willemarck N, Rysman E, Brusselmans K, Van Imschoot G, Vanderhoydonc F, Moerloose K, Lerut E, Verhoeven G, van Roy F, Vleminckx K, et al. 2010 Aberrant activation of fatty acid synthesis suppresses primary cilium formation and distorts tissue development. *Cancer Research* **70** 9453–9462. (doi:10.1158/0008-5472.CAN-10-2324)
- Wu X, Daniels G, Lee P & Monaco ME 2014 Lipid metabolism in prostate cancer. *American Journal of Clinical and Experimental Urology* **2** 111–120.
- Young RM, Ackerman D, Quinn ZL, Mancuso A, Gruber M, Liu L, Giannoukos DN, Bobrovnikova-Marjon E, Diehl JA, Keith B, et al. 2013 Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. *Genes & Development* **27** 1115–1131.
- Yue S, Li J, Lee SY, Lee HJ, Shao T, Song B, Cheng L, Masterson TA, Liu X, Ratliff TL, et al. 2014 Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. *Cell Metabolism* **19** 393–406. (doi:10.1016/j.cmet.2014.01.019)
- Zadra G, Photopoulos C & Loda M 2013 The fat side of prostate cancer. *Biochimica et Biophysica Acta* **1831** 1518–1532. (doi:10.1016/j.bbalip.2013.03.010)
- Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, et al. 2014 A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. *EMBO Molecular Medicine* **6** 519–538. (doi:10.1002/emmm.201302734)
- Zaidi N, Lupien L, Kuemmerle NB, Kinlaw WB, Swinnen JV & Smans K 2013 Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. *Progress in Lipid Research* **52** 585–589. (doi:10.1016/j.plipres.2013.08.005)
- Zhang Q & Wakelam MJ 2014 Lipidomics in the analysis of malignancy. *Advances in Biological Regulation* **54** 93–98. (doi:10.1016/j.jbior.2013.11.001)
- Zhang Z, Hou X, Shao C, Li J, Cheng JX, Kuang S, Ahmad N, Ratliff T & Liu X 2014 PIK1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. *Cancer Research* **74** 6635–6647. (doi:10.1158/0008-5472.CAN-14-1916)
- Zhou BR, Huang QH, Xu Y, Wu D, Yin ZQ & Luo D 2012 Dihydrotestosterone induces SREBP-1 expression and lipogenesis through the phosphoinositide 3-kinase/Akt pathway in HaCaT cells. *Lipids in Health and Disease* **11** 156. (doi:10.1186/1476-511X-11-156)

Received in final form 26 April 2016

Accepted 28 April 2016

Accepted Preprint published online 29 April 2016